Brian G. Feagan, MD

Alimentiv, Inc.; Western University
London, ON, Canada

Disclosure information not submitted.

Presentation(s):

• D0381 - Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12

  Tuesday, October 25, 2022
  10:00 AM – 12:00 PM ET

• D0380 - Impact of Inflammatory Burden on Efficacy of Upadacitinib Maintenance Therapy in Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study

  Tuesday, October 25, 2022
  10:00 AM – 12:00 PM ET